Royalty Report: Drugs, Cancer, Biotechnology – Collection: 28676

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Therapeutic
  • Disease
  • Antibody
  • Drug Discovery
  • Vaccine
  • Diagnostic
  • HPV
  • cell therapy
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28676

License Grant
The Canadian Licensor hereby grants to Licensee a sole and exclusive, non-transferable (other than to an Affiliate with prior written notice to Licensor), royalty bearing license in the Territory, with the right to grant sublicenses, under the Licensed Technology to develop, make, have made, use, import, market, promote, sell and have sold Products within the Field in the Territory.
License Property
Licensor has rights to certain antigen-targeted antibodies that may be effective in the treatment of certain diseases.

Licensed Technology means, collectively, (j) OvaRex®, BrevaRex®, ProstaRex™, AR54, and GivaRex™ their formulations and methods of administration; (k) the Prior Development Technology; (l) Patents, Know-How, and Joint Intellectual Property, (m) all Information relating to those certain antibodies known as OvaRex®, BrevaRex®, ProstaRex™, AR54, and GivaRex™ in the course of any work conducted pursuant to this Agreement, and (n) Improvements.

Therapeutic composition that produce an immune response Altered Immunogenicity USA 9/2/98 09/152,698

Therapeutic Binding Agents against MUC-1 antigen and methods of their use BrevaRex  USA 8/18/00  09/641,833 & USA 11/26/01 09/994,466

Therapeutic method utilizing antigen-antibody complexation and presentation by dendritic cells-Dendritic Cells.

OvaRex   listen (OH-vuh-REX)  A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. OvaRex binds to the CA-125 antigen, which is found on most ovarian cancer cells. Also called oregovomab.

BrevaRex A phase-II trial, activated murine monoclonal antibody developed for treating tumours expressing MUC-1—e.g., breast, prostate, pancreas, renal, lung and colorectal cancers.

ProstaRex(TM) MAb to induce T cells in laboratory studies to a circulating prostate cancer antigen, PSA.

GIVAREX is a product related to gastrointestinal cancer vaccine based on a murine monoclonal antibody and a gastrointestinal cancer pharmaceutical preparations for vaccination consisting of the monoclonal antibody supplied in a proprietary formulation for intravenous, subcutaneous, intraperitoneal or intramuscular injection in humans.

Field of Use
Field means the treatment of any and all therapeutic indications and uses.

Licensee is involved in the development and commercialization of products potentially useful in the prevention, mitigation and treatment of disease.

IPSCIO Record ID: 227239

License Grant
The Canadian Licensor hereby grants to the Canadian Licensee and Licensee hereby accepts (a) in consideration of the up-front payment under hereof, an exclusive worldwide right and license under the Patent Rights, and (b) in consideration of the Net Sales Revenue Royalty hereof, an exclusive worldwide right and license under the Proprietary Rights, exclusive of the Patent Rights, in either case (being (a) or (b) above) to use the B43 Antibody, the B43 Working Cell Bank, and the Data to develop, commercialize, manufacture, make, use and sell Licensed Products solely for Anti-Idiotype Applications, including the right to grant sublicenses to third parties, subject to the terms and conditions of this Agreement.
License Property
Patent Rights means the patent applications referred to this Agreement, together with all continuations, divisionals, continuations-in-part, and any foreign equivalents, and any patents issuing therefrom, including any reissues thereof, related to the Licensed Products and Technology;

Proprietary Rights means the Patent Rights and all copyrights, trademarks, industrial designs and other intellectual property rights or benefits (including Know-How) specifically relating to Anti-Idiotype Applications of the B43 Antibody, the B43 Working Cell Bank and the Data, in each case owned or controlled by Licensor, but excluding the Multi-Epitopic Patent Rights;

Data means, as of November 24, 1995 (the effective date of the Original Agreement), the experimental and clinical data and records of Licensor relating to the B43 Antibody, the B43 Working Cell Bank and the product OVAREX(TM) owned by Licensor;

B43 Antibody means the murine antibody MAb B43.13

MAb-B43 relates to anti-idiotype applications.

B43 Working Cell Bank means Licensors murine working hybridoma cell bank B43.13 of the murine hybridoma clone B43.13 such cell bank being produced at the Charles River Laboratories and used in the OVAREX(TM) program as of November 24, 1995 (the effective date of the Original Agreement);

Anti-Idiotype Applications means the induction of anti-idiotype and/or cellular immune response by administration of a formulation containing an antibody, antibody fragment or antibody derivative for the treatment or prevention of disease. Without limiting the generality of the foregoing, Anti-Idiotype Applications specifically includes the administration of the B43 Antibody for therapeutic or prophylactic purposes;

Field of Use
OvaRex(TM) is based on Licensee's proprietary antibody-based immunotherapeutic approach known as Anti-idiotype Induction Therapy.  Treatment with OvaRex(TM) MAb in late stage ovarian cancer patients with residual disease has been well tolerated in an ongoing open label Phase II study.

IPSCIO Record ID: 28795

License Grant
Licensor, a non-profit cancer treatment and research institution, grants an exclusive, worldwide right and license, including the right to sublicense, to the Biological Materials and the Licensor Program Patents and interest in Joint Program Patents to discover, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Materials and Licensed Products and to practice Licensed Processes.

Licensor grants a nonexclusive research and development license for Licensee to practice the use of Licensor' s cancer vaccines identified in the Licensor Patents and the antigens which they contain, to the extent that Licensor has a Valid Claim on any antigens included in any or all vaccines.

License Property
Licensor has been engaged in research efforts focused on the development of conjugated tumor antigens as cancer vaccines.  Licensor plans to conduct human clinical trials on such cancer vaccines which are expected to generate antisera against tumor antigens.

Biological Material shall mean human blood and lymphocytes obtained from patients enrolled in the Participating Licensor Clinical Trials.

The patents include
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthesis of glycoconjugates of the globo-h epitope and uses thereof;
Synthesis Of The Breast Tumor-Associated Antigen Defined By Monoclonal Antibody MBR-1 And Uses Thereof;
Polyvalent Conjugate Vaccine for Cancer; and,
Optimal Polyvalent Vaccine for Cancer.

Field of Use
Licensee has expertise in the discovery, development and production of monoclonal antibodies using the lymphocytes of naturally exposed or vaccinated donors.

IPSCIO Record ID: 203490

License Grant
This agreement is to develop and commercialize certain of the antibodies produced and evaluated by the Parties pursuant to such collaborative relationship and/or other antibodies generated against the target proteins identified within the collaboration and selected by Licensee for development, and the Parties desire for Licensor to have all rights to those targets and antibodies coming out of the collaborative research that Licensee does not elect to further develop.

For the Screening license, Licensor grants a non-exclusive license under the Licensors Technology and Licensors interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term.  Such license shall not be sublicensable.

For the Development and Commercialization license, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to generate and screen Licensees Mabs; and create Derivatives of Selected Mabs and Licensee Mabs, and develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products for use in the Commercial Field in the Territory.

And, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to use the Selected Targets to generate and screen Licensee Mabs, and develop Licensed Mabs in the Commercial Field in the Territory during the Term.

License Property
Licensor has proprietary immunization and other methods for generating Mabs against cell surface proteins, and possesses certain proprietary cell lines or will acquire cell lines which have cell surface proteins with relevance to ovarian cancer.

Licensor Technology shall mean any Know-How that is and all Patents claiming inventions that are useful or necessary to generate and to screen Mabs binding to a Molecular Target, including without limitation methods of immunization, methods for maintaining and handling cell lines expressing Mabs, production and freezing media, and antibody screening facilitation tools including without limitation CellArrayâ„¢,  controlled by Licensor as of the effective date and during the term, and disclosed by Licensor to Licensee during the Term.

Joint Know-How shall mean any Know-How jointly invented by both Parties in the conduct of the Research, invented by Licensor in the conduct of the Research as a direct result of its use of Licensees Technology, or, invented by Licensee in the conduct of the Research as a direct result of its use of Licensors Technology.

Licensed Product shall mean any pharmaceutical product containing a Licensed Mab.

Cytotoxic Compound shall mean any Cytotoxic compound and all variants, fragments or derivatives thereof, whether produced by a botanical source, natural fermentation or chemical synthesis,  which is, in any case, controlled by Licensee.

Naked Mab Licensed Product shall mean any Licensed Product that is not a Cytotoxin-Coupled Licensed Product.

Antigen shall mean any protein, peptide or carbohydrate or other composition, and/or any fragment, peptide and/or epitope thereof which causes an immune response that produces antibodies.

Field of Use
The Major Indication shall mean an one of prostate cancer, breast cancer, lung cancer, colorectal cancer, non-Hodgkins lymphoma, bladder cancer, melanoma, uterine cancer, leukemia, kidney cancer, head and neck cancer, pancreatic cancer or ovarian cancer.

The Commercial Field shall mean therapeutic products employing Mabs, alone or in conjunction with other ingredients, to treat cancer in humans.

IPSCIO Record ID: 369313

License Grant
Licensor, a non-profit cancer treatment and research institution, grants the exclusive right and license, with the right to sublicense, to make, have made, use, lease and sell the Licensed Products in the Territory for the Field of Use.
License Property
The Invention shall mean the inventions claimed or described in Patent Rights titled Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma associated antigen.
Field of Use
Licensee is developing the MUC-1 peptide-based vaccine BLP-25 for the potential treatment of cancer. It is in phase II trials for non-small cell lung cancer (NSCLC). The MUC-1 mucin secreted by cancer cells has been shown to decrease the activity of certain immune response cells, including killer T-cells, and can inhibit the immune T-cell response by > 70%. BLP-25 is designed to target an immune response to the MUC-1 mucin that is shown by > 90% of common solid tumors.

The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.

IPSCIO Record ID: 28073

License Grant
The Canadian University hereby grants to the Canadian Licensee an exclusive world-wide license, in respect of the Type I Technology and a non-exclusive world-wide license in respect of the Type II Technology, to make use of, or caused to be used, sell and/or sublicense the Technology and any know how associated therewith or which forms a basis thereof whether it is the Scientist's know how, and to manufacture, commercialize, distribute, market, import, export, offer to sell, sell, lease and/or license or sublicense Products on the terms and conditions hereinafter set forth (the License).
License Property
The Scientist of  the University has been engaged in research during the course of which he has developed certain recombinant viral antigens, murine antibody clones and an animal model.

Type I Technology shall mean the recombinant viral antigens and murine antibody clones and Type II Technology shall mean the animal model.

1. Antigens cloned, expressed and purified in the Tyrrell University laboratory as follows

·
Human Hepatitis B(HBV) Core Antigen (short)

·
Duck Hepatitis B(DHBV) Surface Antigen

·
Duck Hepatitis B(DHBV) Polymerase Protein

·
Duck Hepatitis B(DHBV) Core Protein

2. Murine antibody clones developed in the Tyrrell University laboratory as follows

·
Monoclonal Antibody 1D12 to HBV core antigen

·
Monoclonal antibodies 2C12, 2D12, 2C11, 2A12, 4A10, 1F9, 2G11 to HBV surface antigen

·
Monoclonal Antibody 3A8, 2C4 to HBV Polymerase

·
Monoclonal Antibody 1F4 to DHBV Surface Antigen

·
Monoclonal Antibodies 9A8, 8D6, 7G4, 7G5, 7G10, 9F2, 9G8, 1A9, 4A9, 1H5 to DHBV Core Antigen.

3. Animal model as follows

·
Hepatitis B Duck Model

Including any replications of progeny of the above made by the Licensee and, if that which is made by the Licensee, constitutes cells or DNA molecules. Type II Technology includes all modifications, improvements and variants thereof and any data or information in relating thereto including sequence information.

Field of Use
Licensee will be commercializing novel therapeutic approaches to treat diseases, excluding cancer, in humans created by identifiable microbial pathogens.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 28794

License Grant
Licensor, a non-profit cancer treatment and research institution, granted the Company an exclusive, worldwide License under certain U.S. and foreign patents and patent applications owned or controlled by Licensor, or the Licensor's Patents, to develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of therapeutic vaccines for the treatment of various cancers.

Subject to certain limitations, the Company will have the right to subLicense the foregoing rights granted.

Licensor grants an exclusive worldwide right and license under the Patent Rights, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice Licensed Processes in the Field of Use.

Licensor grants an exclusive, as it relates to commercial purposes, and not exclusive as it relates to non-commercial purposes, worldwide right and license under the Clinical Data, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

Licensor grants a non-exclusive worldwide right and license under the Know How, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

License Property
Licensor is the sole owner of certain Patent Rights and Know How relating to Polyvalent Conjugate Vaccines for Cancer.

The patents include, but are not limited to
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthetic Compounds Which Bind To H. Pylori And Uses Thereof;
Alpha-O-Linked Glycycoconjugates with Clustered (2,6)-ST Epitopes, Methods of Preparation and Uses Thereof; and,
Polyvalent Conjugate Vaccine for Cancer.

Field of Use
The Field of Use shall mean monovalent and multi-molecular polyvalent cancer vaccines, except that, for the Globo H antigen, Field of Use shall mean multi-molecular polyvalent cancer vaccines. Multi-molecular polyvalent cancer vaccine means a cancer vaccine containing more that one type of antigen but not in the same molecule.

IPSCIO Record ID: 6797

License Grant
Licensor hereby grants to Licensee a right and license or, in the case of Patents licensed to Licensor under the Licensor In-Licenses, a sublicense, under the Licensed Technology, to make, have made, use, offer to sell, sell and have sold Products except as set forth in this agreement in the relevant Field, and in the Territory.
License Property
Table 1 BR96sFv-PE40 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BR96 sFV-PE40 Program

Patent
  
Description
License Type

Number
Number

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

Table 2 BR96/Drug Conjugate Program

Application
Patent
  
Description
License Type

Number
Number

353,729
5,122,368
  
Linker chemistry having an acylhydrazone linkage through C13 keto group of anthracycline to nonimmunoglobulin ligand. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

96,628

  
Acylhydrazone linkage through C13 keto group of anthracycline to immunoglobulin. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

824,951
5,622,929
  
Anthrecycline ligand conjugates where linkage is an acylhydrazone through C13 keto position of anthracycline. Linker also contains succinimido moiety. Chemistry is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/468,162
5,606,017
  
Anthracycline intermediate having acylhydrazone linkage through C13 keto position of anthracycline and a Michael Addition Receptor. Intermediate in conjugation used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/469,840

  
Process for conjugation using intermediate above with reduced immunoglobulin to increase total drug to antibody yield. Process is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

62,366

  
Enzyme cleavable peptide linker for making cytotoxic drug ligand conjugates. Linkers are used to make second generation BR96-Dox.
Partially-Exclusive for Linkers

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

77,253

  
Immunoconjugates of murine monoclonal antibody BR96, chimeric BR96 and other recombinant antigen binding fragments. Includes single chain and bispecific recombinant constructs.
Exclusive

333,840

  
Methods of treating human carcinoma by administering murine BR96, chimeric BR96 or any recombinant antigen binding construct either by itself or conjugates with various agents. Also includes diagnostic kits.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

08/285,936

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

08/487,860

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

60/030/367

  
Branched peptide linker for linking thiol group on targeting ligand to two or more drug moieties.
Partially-Exclusive for Linkers

5,204,244
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,202,238
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,482,856
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

Table 3 G28-5 SfV/Immunotixin Program

The patents and patent applications (the “Washington Patents”), together with the know-how related thereto, sublicensed under the Washington Agreement constitute the G28-5 sFv/Immunotoxin Program. [Exclusive]

Table 4 BD1 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BD1 Program

Application
Patent
Description
License Type

Number
Number

08/245,754
5,541,110
Isolated oligonucleotide sequence encoding Bryodin 1, recombinant vectors and plasmids, and transfected host cells.
Exclusive

08/597,731

Methods for the recombinant production of Bryodin 1 and Bryodin 1-ligand fusion proteins.
Exclusive

08/324,301
5,597,569
Ribosome-inactivating protein Bryodin 2 in an isolated form, linked to a ligand as a conjugate or a fusion protein, pharmaceutical compositions, nucleotide sequence, transfected host cells and recombinant production.
Exclusive

Table 5 ADEPT Program

The following patents and patent applications, together with the know-how related thereto, constitute the ADEPT Program

Application

Number
Patent
Description
License Type

(filed 5/7/96)
Number

Recombinant L49sFv-¨ lactamase fusion proteins which recognize p97 melanoma antigen and activate-cephalosporin derivatized prodrug molecules.
Exclusive

211,301
4,975,278
Methods for delivering cytotoxic agents to tumor cells by administering an effective amount of at least one antibody-enzyme conjugate, wherein the antibody is specific for a tumor associated antigen and the enzyme converts at least one weakly cytotoxic prodrug to its corresponding cytotoxic parental form; and the administration of an effective amount of the prodrug.
Non-Exclusive

Table 6 Residual Program

The following patents and patent applications, together with the know-how related thereto, constitute the Residual Program

Application
Patent
Description
License Type

Number
Number

684,759
4,935,495
Monoclonal antibodies, Fab, F(ab1)2 or Fv fragments thereof which compete for binding with L6 to its antigen.
Partially-Exclusive for Cancer

776,321
4,906,562
Methods for detecting malignancy using L6 or other monoclonal antibodies or fragments thereof which compete with L6 for binding to its antigen.
Exclusive

523,309
5,091,177
Method for reducing population of tumor cells using L6 or monoclonal antibodies which compete for binding with L6 to its antigen.
Exclusive

443,696
5,242,824
Monoclonal antibody BR64 and antigen binding fragments thereof.
Exclusive

08/726,528

Monoclonal antibodies and recombinant antigen binding molecules which recognize the G733-1 but not G733-2 antigen. Specifically BR110.
Partially-Exclusive for Cancer

527,227
5,165,922
Method of treating breast carcinoma in an unresponsive patient by first administering monoclonal antibody L6 followed by administration of a chemotherapeutic agent.
Exclusive

5,663,158
Method for treating vascular leak syndrome.
Non-Exclusive

The Residual Program also includes antibodies L6, L49, BR64, BR110, OV578.1 and OV569.1 [Exclusive]

Field of Use
Field shall be the treatment and diagnosis of cancer in humans.

The Field with respect to Licensed Technology for which Licensee is granted a right and license that is partially exclusive shall be

(i) if this Agreement indicates that such license is partially exclusive for linkers, all monoclonal antibody targeting applications; or (ii) if the agreement indicates that such license is partially exclusive for cancer, the treatment and diagnosis of cancer in humans. The Field with respect to Licensed Technology for which Licensee is granted a right and license that is non-exclusive shall be the treatment and diagnosis of cancer in humans. Notwithstanding the foregoing, the Field with respect to the G28-5 Licensed Technology shall be for the use of the antibody G28-5 fused with a toxin for the treatment of cancer in humans.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 324838

License Grant
Licensor, a cancer treatment and research institution, grants an exclusive option to take an exclusive world-wide License under Licensed Patents and Technology.

Upon exercise of its option rights, Licensee shall have the exclusive rights in the Territory, with the right to grant sublicenses, to make, have made, use and sell, licensed products utilizing the Licensed Patents and Technology and products utilizing Licensed Technology.

License Property
The patent is titled Prostate-Specific Membrane Antigen.

Gene technology means that part of Licensed technology that pertains to any DNA encoding the prostate specific membrane (PSM) antigen or any portion of the PSM antigen and any DNA, cDNA, and other derivative or portion of said gene that expresses the PSM antigen, including, but not limited to, diagnostic methods employing DNA probes or PCR techniques to detect prostate cancer and gene therapy applications.

Know-how means the skill or ingenuity based upon the body of knowledge and data which comprise all of the methods, processes, designs, engineering information, trade secrets, and other information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees-356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen, Confidential information and Gene technology which Licensor develops, employs in its own activities, or has available for use prior to or during the term of this Agreement.

Licensed technology means information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees -356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen owned by Licensor as of the effective date or acquired during the term of this agreement; including without limitations, inventions, biological materials, computer programs, technical data, apparatus and Know-how, Gene technology and confidential information, whether patentable or unpatentable.

Licensees-356 is a prostate cancer monoclonal antibody conjugate.

Field of Use
The agreement relates to the detection of prostate cancer and gene therapy applications.

The Parties have a development program involving the prostate specific membrane antigen (PSM) and Licensees prostate cancer monoclonal antibody conjugate, -356.

IPSCIO Record ID: 26043

License Grant
The Licensor of England granted the Licensee an exclusive worldwide right and license in the Intellectual Property to research and develop Products in the Field antibody based products for the development and manufacture of immunological products.
The Licensee shall have the right to grant Sub-licenses.
License Property
The Licensor is an oncology focused technology transfer and development company.

CD55 antigen may have potential in the treatment of several indications including breast, ovarian and colorectal cancers.

Field of Use
Field means the field of use for the immunotherapeutic treatment and/or diagnosis of diseases.

IPSCIO Record ID: 266837

License Grant
For the Research License Grants, Licensor shall automatically be deemed to have granted to Licensee a non-exclusive, worldwide license under the Licensor Technology solely to conduct the Research Program.

For the Exclusive License Grants, with respect to the First Exclusive Antigen, and the Option Exercise Fee  with respect to the Second Exclusive Antigen, and commencing as of the date Licensor has received the ADC Access Fee or Option Exercise Fee, as the case may be, from Licensee, Licensor shall automatically be deemed to have granted to Licensee an exclusive, even as to Licensor, license under the Licensor Technology, with the right to sublicense to discover, develop, have developed, make, have made, import, use, offer for sale, and sell Licensed Products that bind specifically to the Exclusive Antigen within the Field in the Territory.

For the Grant of Option, Licensor hereby grants Licensee an option to obtain the Exclusive License of this Agreement to the Second Exclusive Antigen during the Option Period.

For the Replacement Right; Dropped Antigen,  Licensee shall have the right to designate the first exclusive antigen as a Dropped Antigen for purposes of this Agreement by providing Licensor with written notice of same.  Licensee shall have the right to designate one (1) additional Designated Antigen as a replacement for the Dropped Antigen in accordance with  the procedure.

License Property
The patents relate to tumor inhibitors.

The patent applications include Pentapeptide Compounds and uses related thereto; Drug Conjugates and their uses for Treating Cancer, an Autoimmune Disease or an Infectious Disease; and, Monomethylvaline Compound Capable of Conjugation to Ligands.

ADC technology can be widely employed to increase the therapeutic potential of monoclonal antibodies through stable attachment to cell-killing drug payloads.

Field of Use
Field means the treatment and diagnosis of conditions and diseases in humans and animals; provided that with respect to the use of the BMS Technology the Field shall be limited to monoclonal antibody targeting applications.

The proprietary ADC technology for use with Licensee's proprietary antibodies for the treatment of cancer.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 203339

License Grant
The Licensor of Finland grants to Licensee an exclusive right and license, with the right to grant sublicenses under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the Field in the Licensee Territory, except in the Licensor Field in the Licensor Territory; and a non-exclusive right and license, with the right to grant sublicenses, under the Licensor Patents and Know-How, to perform research and preclinical development activities, using the Powder to be provided to Licensor, except in the Licensor Field in the Licensee Territory.
License Property
The Product shall mean any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

The Fareston Product shall mean the Orion Product in 60 mg tablet form containing Toremifene that was promoted in the USA under the brand name Fareston by Shire prior to the Restatement Date for use in the Breast Cancer Field.

Toremifene shall mean [tore mi f ene citrate and/or the Z-isomer of 4-chloro-1, 2 diphenyl-1-(4-(2-(N,N-dimethylamino)-ethoxy) – phenyl]- 1 -butene].

Field of Use
The field means all uses of a Product in humans, with a current use of treatment of prostate cancer. The Parties expressly acknowledge that the use of Product in the field of animal health is excluded from the scope of this Agreement.

IPSCIO Record ID: 372584

License Grant
Licensor grants a non-exclusive license, including the right to sublicense solely to Affiliates of Licensee, in the Territory under Licensor Use Patent Claims which are determined to include Infringing Claims for use in connection with Covered ODNs outside the Field to the extent otherwise not prohibited by this Agreement.

Licensor grants a non-exclusive license, including the right to sublicense to Permitted Sublicensees, in the Territory under Licensor Process Patent Claims for use in connection with the manufacture of Covered ODNs.

For the Research license,  Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any rights to use the Licensor Technology for the sale or manufacture for sale of products or processes.

For Licensees Commercialization Rights, Licensee shall have the right to elect, upon notice to Licensor, to market the Product for the Licensees Indication to Specialty Dermatologists as provided.

License Property
The Licensed Product means any Product, Combination Product, Vaccine Product, Research Product, Research Combination Product or Research Vaccine Product.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensee.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Intermediate indications mean all treatment non-Hodgkins lymphoma and prostate cancer (except for Japan), all treatment of Ovarian cancer, third-line treatment of breast cancer or later treatment of breast cancer,  second-line or later treatment of NSCLC, second-line or third-line  treatment of colorectal cancer.

Minor indication means all treatment of melanoma,  T cell lymphoma, renal cell carcinoma, pancreatic cancer, hematological malignancies (other than non-Hodgkins lymphoma), bladder cancer, uterine cancer, cervical cancers and any other cancers in the field.

Licensees Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Field of Use
The field of use includes the treatment, control or prevention of cancer in humans.

Licensee owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 28485

License Grant
The Licensee entered into an exclusive, worldwide License Agreement with a University for the AC Technology.
License Property
The AC Technology is based on the concept of haptenization.  

Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine.  By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.

Field of Use
The Licensee is a development stage biotechnology company specializing primarily in the development and future commercialization of individualized cancer vaccines.  Our proposed vaccines consist of autologous (the patient's own) cancer cells that have been treated with a chemical ('haptenized') to make them more visible to the patient's immune system.  Our previous clinical trials for the AC Vaccine have concentrated on melanoma and ovarian carcinoma, which are our primary indications, and non-small cell lung cancer.

IPSCIO Record ID: 356291

License Grant
For the General Grant to the German Licensee, Licensor grants an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Develop the Product in the Licensees Territory in the Field; and during the Term, an exclusive license, including the right to sublicense through multiple tiers, under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to Commercialize the Product in the Field in the Licensees Territory; and during the Term, a non-exclusive, perpetual, worldwide license under the Licensor Technology, Licensor Platform Technology, Licensor Manufacturing Technology and Licensors interest in the Joint Technology, to perform Development Activities in the Licensor Territory solely in accordance with the Development Plan and for Sole-Funded Activities by Licensee.

For the Manufacturing Grant to Licensee, Licensor grants a co-exclusive license, including the right to sublicense through multiple tiers, under the Licensor Manufacturing Technology, Licensors interest in the Joint Technology, Licensor Patents and the Licensor Platform Technology, to Manufacture the Product for Development worldwide in the Field and for Commercialization in the Field in the Licensee Territory.

By this agreement, Licensor will have the exclusive commercialization rights in the United States and Canada and Licensee will have the exclusive commercialization rights in the rest of the world.

License Property
Licensor has developed and is currently further developing the novel compound xx414.

Compound xx414 means a bispecific polypeptide containing a Prostate Specific Membrane Antigen or PSMA Binding derived from murine antibody 107-1A4 and a CD3 Binding Domain derived from murine antibody CRIS-7 (xx414), and any back-up or follow-on compound comprised of a PSMA Binding Domain with or without other Binding Domains, including both a PSMA Binding Domain and a CD3 Binding Domain or both a PSMA Binding Domain and a Binding Domain other than CD3 Binding Domain; and any modification or derivative of the foregoing (including conjugated or mono/multi-specific forms thereof).

CD3 Antigen means the T cell receptor (TCR) complex or any one or more of the CD3 group of cell surface molecules found on T-cells, including TCRa, TCRb, CD3y, CD3d, and CD3e.

CD3 Binding Domain means a Binding Domain that binds the CD3 Antigen and which has greater binding selectivity for the CD3 Antigen versus other antigens (and, for purposes of this definition, disregarding any residual binding activity).

Product Inventions means all Inventions relating to a PSMA Binding Domain, including Inventions relating to composition of matter, method of use and method of manufacture of the Product.

PSMA Antigen means prostate specific membrane antigen (PSMA), also known as the enzyme glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), or NAAG peptidase.

The patents include
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods,
CD3 Binding Polypeptides, Single Chain Multivalent Binding Proteins with Effector Function, Heterodimer Binding Proteins and Uses Thereof, and, Polypeptides Heterodimers and Uses Thereof.

Field of Use
The collaboration agreement is for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, which activates host T-cell immunity specifically against cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.

Field means all fields of use, including therapeutic, palliative, prophylactic, diagnostic and research use, in human and animals.

Licensee has significant experience in the development of pharmaceutical products;

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.